Inhaled Insulin’s Last True Believer: An Interview with Alfred Mann
Executive Summary
The following is an excerpt from an 1interview with Mannkind founder Alfred Mann, published in the September issue of FDC-Windhover's IN VIVO. Mann explains his conviction that inhaled insulin will be a blockbuster product - despite the commercial failure of Exubera and the decision of other sponsors to drop development of other versions.